Abbott (NYSE:ABT) presented real-world data this week showing that use of its FreeStyle Libre glucose monitoring system reduced prolonged hypoglycemia and helped users achieve better glucose control.
At the 12th Advanced Technologies & Treatments for Diabetes meeting in Berlin, the company showcased a real-world evidence data set that included roughly 500,000 FreeStyle Libre system users.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott touts real-world data for FreeStyle Libre glucose monitor appeared first on MassDevice.
from MassDevice https://ift.tt/2EowOOM
Cap comentari:
Publica un comentari a l'entrada